Alnylam Pharmaceuticals (LTS:0HD2) Receivables Turnover : 1.52 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Alnylam Pharmaceuticals Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Alnylam Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $494 Mil. Alnylam Pharmaceuticals's average Accounts Receivable for the three months ended in Mar. 2024 was $325 Mil. Hence, Alnylam Pharmaceuticals's Receivables Turnover for the three months ended in Mar. 2024 was 1.52.

Alnylam Pharmaceuticals Receivables Turnover Historical Data

The historical data trend for Alnylam Pharmaceuticals's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Receivables Turnover Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

7.11

6.78

5.61

4.75

6.46

Alnylam Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Receivables Turnover	Get a 7-Day Free Trial															1.40	1.45	2.75	1.35	1.52

Competitive Comparison of Alnylam Pharmaceuticals's Receivables Turnover

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alnylam Pharmaceuticals's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Receivables Turnover falls into.

Alnylam Pharmaceuticals Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Alnylam Pharmaceuticals's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	1828.292	/ (	(237.963	+	327.787)	/	2 )
=	1828.292	/	282.875
=	6.46

Alnylam Pharmaceuticals's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

	Receivables Turnover (Q: Mar. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Mar. 2024 ))	/	count )
=	494.333	/ (	(327.787	+	321.377)	/	2 )
=	494.333	/	324.582
=	1.52

Alnylam Pharmaceuticals (LTS:0HD2) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Alnylam Pharmaceuticals Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (LTS:0HD2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (LTS:0HD2) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (LTS:0HD2) Headlines

No Headlines